No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Betta Pharmaceuticals Co., Ltd. is a Chinese pharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of oncology treatments. Among its key offerings are Icotinib hydrochloride, an orally taken epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and Ensartinib hydrochloride, an anaplastic lymphoma kinase (ALK) inhibitor, both utilized in the management of non-small-cell lung cancer. Founded in 2003, the firm is headquartered in Hangzhou, China.
www.bettapharma.comNo one on the platform currently holds 300558.SZ.
No tracked institution reports a position in 300558.SZ as of their last filing.
No one on the platform has traded 300558.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 3.8% | 5.3% | 9.0% | — | — | — |
| Rev. Growth % | 24.8% | 14.1% | ||||
| Profit Margin % | 8.5% | 11.9% | 18.1% | |||
| Free Cash Flow Margin % | 8.2% | -7.3% | -8.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $4.1B | +17.7% | $1.37 | $1.37–$1.37 | — | 1 |
| 2027 | $4.7B | +14.7% | $1.78 | $1.78–$1.78 | — | 1 |
| 2028 | $5.9B | +25.3% | $2.43 | $2.43–$2.43 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-21 | $0.12 | $0.16 | +33.4% |
| 2026-04-22 | $0.54 | $-0.03 | -105.1% |
| 2026-04-22 | $0.54 | $0.56 | +3.7% |
| 2025-10-27 | $0.25 | $0.42 | +68.0% |
| 2025-08-19 | $0.39 | $0.10 | -74.4% |
| 2025-04-24 | $0.45 | $0.24 | -46.7% |
| 2025-04-17 | $0.38 | $-0.03 | -107.9% |
| 2024-10-28 | $0.22 | $0.46 | +109.1% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300558.SZBetta Pharmaceuticals Co., Ltd. | $46.21 | -1.13% | $19.6B | — |
| 000623.SZJilin Aodong Pharmaceutical Group Co., Ltd. | $17.40 | -1.02% | $20.8B | — |
| 002262.SZJiangsu Nhwa Pharmaceutical Co., Ltd. | $21.65 | -0.64% | $22.0B | — |
| 002755.SZBeijing Aosaikang Pharmaceutical Co., Ltd. | $11.26 | -1.23% | $10.5B | — |
| 300723.SZApicHope Pharmaceutical Co., Ltd |
| $33.33 |
| -1.97% |
| $15.1B |
| — |
| 600380.SSJoincare Pharmaceutical Group Industry Co.,Ltd. | $9.23 | -1.07% | $16.9B | — |
| 600511.SSChina National Medicines Corporation Ltd. | $26.25 | -0.61% | $19.8B | — |
Source: Financial Modeling Prep · peers by sector/industry